James Healy, Director at Y-mAbs Therapeutics, Inc. (YMAB), bought 90,000 shares at $28.00 ($2.5M) on 2019-10-30, disclosed to the SEC on 2019-11-01.
Open-market purchase of $2.5M YMAB by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| RAPP | BUY | 2024-06-10 | $9.5M | — | Filing → |
| AVBP | BUY | 2024-01-31 | $8.0M | — | Filing → |
| NTRA | SELL | 2023-12-22 | $37.8M | — | Filing → |